Company intelligence / Profile preview

Minomic International

Macquarie Park (Sydney), New South Wales, Australia

Ownership: Private
Development stage: Other

Overview

MiCheck® Prostate, Minomic's flagship blood test, has shown 95% sensitivity and superior specificity in clinical studies, and is commercially available in the US (with Medicare reimbursement) and Australia; it has reduced false positives and unnecessary biopsies compared to standard of care, with strong clinical validation including a major Australian study (Sept 2022)[1][5][6].

Therapeutic areas: Oncology
Modalities: Diagnostic testProtein biomarker panel (blood-based)
Industry: Protein Biomarker Diagnostics

Partnerships

Sonic Healthcare (Australia: Pathology network)20/20 GeneSystems (U.S. distribution partner)Macquarie University (research collaboration)

Beyond the preview

Go deeper on Minomic International.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Minomic International.

Explore the full profile